2MONROE A T,WALIA R,ZLOTECKI R A,et al.Tracheobronchi-al amyloidosis a case report of successful treatment with external beam radiation therapy[J].Chest,2004,125(2):784 -789.
3LEUNG N,DISPENZIERI A,FERVENZA F C,et al.Renal response after high-dosemelphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis[J].Am J Kidney Dis,2005,46(2):270 -277.
4Daniels JT, Cury JD, Diaz J. An unusual cause of postobstructive pneumonia[J]. Chest, 2007,131 (3) : 930-933.
5Berk JL, Keane J, Seldin DC, et al. Persistentpleural effusions in primary systemic amyloidosis: etiology and prognosis[J]. Chest, 2003, 124(3): 969-977.
6Berk JL, Regan A, Skinner M. Pulmonary and tracheobron-chial amyloidosis[J]. Semin Respir Crit Care Med 2002; 23: 155-65.
7Merlini G, Bellotti V. Molecular mechanisms of amyloidosis[J]. New England Journal of Medicine, 2003, 349(6): 583-596.
8Teng J, Turbat-Herrera EA, Hen'era GA. Role of translational research advancing the understanding of the pathogenesis of light chain-mediated glomemlopathies[J]. Pathology International, 2007, 57(7): 398-41.
9Wechalekar AD, Goodman HJ, LaehmannIII , et al. Safety and efficacy of risk-adapted eyelophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis[J]. Blood, 2007, 109(2): 457-464.
